Background: In adolescents and young adults (AYAs) with cancer, the importance of patient-centered research outcomes is increasingly acknowledged and there is a need for consensus on the most relevant outcomes. This review provides a comprehensive overview of outcomes relevant to AYAs with cancer in order to develop an AYA-specific core outcome set (COS) as part of the European project STRONG-AYA. Methods: A literature search was conducted to identify relevant articles in five databases. Each article was reviewed by two independent researchers, using Rayyan (an online tool) to screen articles by their title/abstract and then by their full text. Subsequently, the data were extracted using a predefined, tailored extraction framework. Results: In total, 17,301 articles were screened, of which 1631 were included in the analyses. Registry studies (52.9%) were the most used study type. Well-represented continents were North America (50.3%) and Europe (27.8%). Of the five core areas, functioning (47.0%) and epidemiology (44.9%) were covered most often, followed by physiological/clinical (42.4%), resource use (6.1%), and adverse events (4.5%). The outcome domains that were represented the most include mortality/survival (43.1%), delivery of care (23.4%), outcomes relating to neoplasms (22.7%), and emotional functioning/well-being (19.2%). Conclusions: This literature review provides a foundation for the development of an AYA-specific COS for improving the relevance and efficiency of measuring outcomes, the pooling of (international) research data, and the value of care for current and future AYAs with cancer. Finalization and refinement of the COS should be a priority for future research.
Cancer in Adolescents and Young Adults (AYAs) represents a unique biological intersection, encompassing malignancies typical of both paediatric and older adults, as well as age-specific cancers. Yet, diagnostic and treatment approaches are not tailored to AYAs, potentially overlooking age-specific molecular characteristics. This review examines genomic differences between AYAs and paediatric and older patients, emphasising trends in cancer driver genes and identifying knowledge gaps that limit our understanding of AYA cancer biology. Across studies and cancer types, the AYA age range varies but is typically defined as 15-39 years. Remarkably, for nearly half of cancers diagnosed in AYAs, little or no literature exists on genomic differences or similarities compared to other age groups. Common cancers like testicular cancer and gynaecological cancer are underrepresented, while other typical AYA cancers such as thyroid cancer entirely lack comparative literature. In contrast, less common AYA cancers such as lung cancer and colorectal cancer are investigated extensively. Although genomic differences are reported across cancer types and in pan-cancer analyses, findings are often not generalisable to relevant subtypes or inconsistent, and insights gained are limited by the use of single-gene assays or small gene panels. This review reveals an imbalance between the global incidence of AYA cancers and the scope of comparative genomic studies, as well as a lack of broader comprehensive molecular profiling. Addressing these gaps through broader genomic research, particularly in underexplored cancers, is essential to determine whether AYA tumour biology is indeed distinctive, and how age-appropriate, genomics-driven precision oncology should be delivered.
Purpose Tumour genomic profiling, including whole genome sequencing (WGS), offers opportunities for refined diagnosis and personalised treatment for adolescents and young adults (AYAs) with advanced or poor prognostic cancer. This study explores AYAs’ attitudes towards receiving WGS in standard oncological care, their preferences for the communication of results and the perceived impact of these results. Methods Semistructured interviews were conducted with AYAs (aged 18–39 years at initial cancer diagnosis). Interviews were transcribed and analysed thematically using an inductive approach in NVivo (V.12). Results 16 AYAs participated. Analysis revealed five themes: (1) confidence in the current WGS procedure; (2) challenges in understanding and communicating purpose and results of WGS; (3) dual emotional impact of WGS results; (4) high value placed on hereditary information for self and loved ones and (5) balancing altruism and personal risk in genomic data sharing. Conclusion AYAs with advanced cancer generally value WGS, even when results have no immediate clinical consequences. They describe benefits such as hope, reassurance and the opportunity to help future patients. However, misunderstandings about its purpose, difficulties in interpreting genomic findings and limited awareness of potential hereditary implications may limit its optimal use. Strengthening communication with age-appropriate, accessible explanatory materials will be essential to ensure AYAs understand the purpose and potential outcomes of WGS and can fully benefit from its implementation.